Boston Partners Has $696.34 Million Stake in Gilead Sciences, Inc. (GILD)

Boston Partners lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,838,102 shares of the biopharmaceutical company’s stock after selling 379,895 shares during the period. Gilead Sciences comprises 0.9% of Boston Partners’ portfolio, making the stock its 24th largest holding. Boston Partners owned about 0.75% of Gilead Sciences worth $696,340,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Seizert Capital Partners LLC lifted its position in Gilead Sciences by 4.6% during the first quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock valued at $42,964,000 after purchasing an additional 27,547 shares during the period. Linscomb & Williams Inc. lifted its position in Gilead Sciences by 3.0% during the first quarter. Linscomb & Williams Inc. now owns 5,275 shares of the biopharmaceutical company’s stock valued at $358,000 after purchasing an additional 154 shares during the period. Investment Centers of America Inc. lifted its position in Gilead Sciences by 7.2% during the first quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock valued at $1,979,000 after purchasing an additional 1,958 shares during the period. HealthInvest Partners AB lifted its position in Gilead Sciences by 3.5% during the first quarter. HealthInvest Partners AB now owns 117,000 shares of the biopharmaceutical company’s stock valued at $7,947,000 after purchasing an additional 4,000 shares during the period. Finally, Capital Asset Advisory Services LLC bought a new position in Gilead Sciences during the second quarter valued at approximately $875,000. Hedge funds and other institutional investors own 73.98% of the company’s stock.

Gilead Sciences, Inc. (GILD) opened at 83.04 on Wednesday. The firm’s 50-day moving average is $81.55 and its 200 day moving average is $71.93. The company has a market cap of $108.44 billion, a price-to-earnings ratio of 9.02 and a beta of 1.14. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The business had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. During the same quarter in the prior year, the firm earned $3.08 earnings per share. The company’s revenue for the quarter was down 8.2% compared to the same quarter last year. On average, equities research analysts predict that Gilead Sciences, Inc. will post $8.76 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 28th. Stockholders of record on Friday, September 15th were issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.50%. The ex-dividend date of this dividend was Thursday, September 14th. Gilead Sciences’s payout ratio is 22.58%.

In other news, CFO Robin L. Washington sold 51,820 shares of the business’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the transaction, the chief financial officer now owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Gregg H. Alton sold 25,000 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $82.65, for a total transaction of $2,066,250.00. The disclosure for this sale can be found here. Insiders have sold 486,819 shares of company stock valued at $39,298,919 in the last ninety days. Insiders own 1.30% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://sportsperspectives.com/2017/10/11/boston-partners-has-696-34-million-stake-in-gilead-sciences-inc-gild.html.

GILD has been the topic of a number of research analyst reports. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research report on Thursday, September 7th. Jefferies Group LLC restated a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a research report on Tuesday, July 4th. Zacks Investment Research upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $79.00 price objective on the stock in a research report on Monday, July 17th. Vetr downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $75.40 price objective on the stock. in a research report on Wednesday, June 21st. Finally, Deutsche Bank AG initiated coverage on shares of Gilead Sciences in a research report on Friday, June 23rd. They set a “buy” rating and a $79.00 price objective on the stock. Twelve analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $85.66.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply